Literature DB >> 19119095

The impact of psoriasis on health care costs and patient work loss.

Joseph F Fowler1, Mei Sheng Duh, Ludmila Rovba, Sharon Buteau, Lisa Pinheiro, Francis Lobo, Jennifer Sung, Joseph J Doyle, Andrine Swensen, David A Mallett, George Kosicki.   

Abstract

BACKGROUND: There are few comprehensive estimates of the cost of psoriasis in the United States.
OBJECTIVE: We sought to quantify the incremental direct medical and indirect work loss costs associated with psoriasis.
METHODS: A de-identified claims database from 31 self-insured employers during the period 1998 to 2005 was used. Patients with at least two psoriasis diagnosis claims (N = 12,280) were compared with 3 control subjects (matched on year of birth and sex) without psoriasis. Multivariate two-part regression analysis was used to isolate the incremental cost of psoriasis by controlling for comorbidities and other confounding factors.
RESULTS: After multivariate adjustment, the incremental direct and indirect costs of psoriasis were approximately $900 and $600 (P < .001) per patient per year, respectively. LIMITATIONS: The database used in this study does not contain information on patient out-of-pocket costs or loss of productivity costs at work.
CONCLUSION: The incremental cost of psoriasis is approximately $1500 per patient per year, with work loss costs accounting for 40% of the cost burden.

Entities:  

Mesh:

Year:  2008        PMID: 19119095     DOI: 10.1016/j.jaad.2008.06.043

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  25 in total

1.  Combining mechanism-based prediction with patient-based profiling for psoriasis metabolomics biomarker discovery.

Authors:  QuanQiu Wang; Thomas S McCormick; Nicole L Ward; Kevin D Cooper; Ruzica Conic; Rong Xu
Journal:  AMIA Annu Symp Proc       Date:  2018-04-16

2.  Psoriasis and psoriatic arthritis: a public health agenda.

Authors:  Charles G Helmick; Jeffrey J Sacks; Joel M Gelfand; Bruce Bebo; Hyewon Lee-Han; Tiffany Baird; Chris Bartlett
Journal:  Am J Prev Med       Date:  2013-04       Impact factor: 5.043

3.  Early tissue responses in psoriasis to the antitumour necrosis factor-α biologic etanercept suggest reduced interleukin-17 receptor expression and signalling.

Authors:  A Johnston; A M Guzman; W R Swindell; F Wang; S Kang; J E Gudjonsson
Journal:  Br J Dermatol       Date:  2014-06-24       Impact factor: 9.302

4.  Prevalence of psoriasis among adults in the U.S.: 2003-2006 and 2009-2010 National Health and Nutrition Examination Surveys.

Authors:  Charles G Helmick; Hyewon Lee-Han; Shawn C Hirsch; Tiffany L Baird; Christopher L Bartlett
Journal:  Am J Prev Med       Date:  2014-04-18       Impact factor: 5.043

Review 5.  Current and potential immune therapies and vaccines in the management of psoriasis.

Authors:  Benjamin H Kaffenberger; Grace L Lee; Kelly Tyler; Derek V Chan; Wael Jarjour; Maria E Ariza; Marshall V Williams; Henry K Wong
Journal:  Hum Vaccin Immunother       Date:  2014-02-03       Impact factor: 3.452

6.  Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States.

Authors:  Reginald Villacorta; Joel W Hay; Andrew Messali
Journal:  Pharmacoeconomics       Date:  2013-09       Impact factor: 4.981

Review 7.  Large-scale, prospective, observational studies in patients with psoriasis and psoriatic arthritis: A systematic and critical review.

Authors:  Sue Langham; Julia Langham; Hans-Peter Goertz; Mark Ratcliffe
Journal:  BMC Med Res Methodol       Date:  2011-03-31       Impact factor: 4.615

8.  Ustekinumab: differential use in psoriasis.

Authors:  Elizabeth E Uhlenhake; David A Mehregan
Journal:  Clin Cosmet Investig Dermatol       Date:  2011-07-01

9.  Keratinocyte apoptosis in epidermal remodeling and clearance of psoriasis induced by UV radiation.

Authors:  Sophie C Weatherhead; Peter M Farr; David Jamieson; Jennifer S Hallinan; James J Lloyd; Anil Wipat; Nick J Reynolds
Journal:  J Invest Dermatol       Date:  2011-05-26       Impact factor: 8.551

10.  Nail psoriasis as a severity indicator: results from the PsoReal study.

Authors:  Marc A Radtke; Anna K Langenbruch; Ines Schäfer; Katharina Herberger; Kristian Reich; Matthias Augustin
Journal:  Patient Relat Outcome Meas       Date:  2010-12-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.